Document Detail


Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency.
MedLine Citation:
PMID:  12897104     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: In congenital or acquired antithrombin III-deficient patients undergoing haemodialysis, coagulation or residual blood in the blood circuit and dialyser is commonly observed under anticoagulation with heparin. Argatroban, a synthetic thrombin antagonist, directly inhibits thrombin activity in a manner that is different from that of heparin, thereby displaying an anticoagulating effect without the activation of antithrombin III. For this reason, the anticoagulating effect of argatroban in haemodialysis patients with antithrombin III deficiency was investigated. METHODS: A retrospective nationwide survey was conducted among patients with congenital or acquired antithrombin III deficiency who had undergone haemodialysis with argatroban as an anticoagulant from April 1996 to April 2000. Inclusion criteria were patients with antithrombin III activity <70% of normal, and patients in whom blood coagulation or residual blood in the extracorporeal circuit could not be prevented by the use of heparin during haemodialysis. RESULTS: Of 80 patients who underwent haemodialysis with argatroban, 59 met the inclusion criteria. Compared with the data before the administration of argatroban, significant improvements of residual blood in the dialyser and arterial and venous drip chambers were observed at the last administration of argatroban. A significant rise in antithrombin III activity was also observed. Among 80 safety analysis cases, no adverse events were reported in 66 patients (82.5%). As severe adverse events, one showed bleeding tendency and one had prolongation of prothrombin time. CONCLUSION: Argatroban was an effective and safe anticoagulant for haemodialysis in patients with congenital or acquired antithrombin III deficiency.
Authors:
Kazuo Ota; Tadao Akizawa; Yoshihei Hirasawa; Tetsuzo Agishi; Noriaki Matsui
Related Documents :
14507564 - Perioperative use of the thrombelastograph in patients with inherited bleeding disorders.
6085194 - Fibrinolytic activators and inhibitors in terminal renal insufficiency and in anephric ...
21646304 - Evidence that venous hypertension causes stasis dermatitis.
21679504 - Impact of allergic rhinitis on bronchi: an 8-year follow-up study.
10966254 - Spectral analysis of systemic arterial pressure and heart rate signals of patients with...
10724084 - Postural sway of the affected and nonaffected pelvis and leg in stance of hemiparetic p...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association     Volume:  18     ISSN:  0931-0509     ISO Abbreviation:  Nephrol. Dial. Transplant.     Publication Date:  2003 Aug 
Date Detail:
Created Date:  2003-08-04     Completed Date:  2003-11-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8706402     Medline TA:  Nephrol Dial Transplant     Country:  England    
Other Details:
Languages:  eng     Pagination:  1623-30     Citation Subset:  IM    
Affiliation:
Tokyo Women's Medical University, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Anticoagulants / adverse effects,  therapeutic use*
Antithrombin III Deficiency / epidemiology*
Female
Hematocrit
Humans
Kidney Failure, Chronic / therapy*
Male
Middle Aged
Pipecolic Acids / adverse effects,  pharmacology*
Renal Dialysis*
Retrospective Studies
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Pipecolic Acids; 74863-84-6/argatroban

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reduction of hypotensive side effects during online-haemodiafiltration and low temperature haemodial...
Next Document:  Repeated femoral vein puncturing for maintenance haemodialysis vascular access.